Gene therapy increases survival for end-stage head and neck cancer
...iety of Gene Therapy annual meeting in Boston.
introgen Therapeutics, Inc., reported results of its phase ...ip analysis reveals gene sequence.
Creation of
introgen
Roth found little interest in gene therapy fro...pharmaceutical companies, so in 1994 he co-founded
introgen working through M. D. Anderson's Office of Technol...
Colgate To Develop Anti-Cancer Toothpastes And Mouthwashes
...almolive Company has entered into an alliance with
introgen Therapeutics to market oral health care formulatio...
Towards this end Colgate purchased $20 million of
introgen shares with exclusive rights over the products that are produced by Introgen.
introgen has a wide range of molecular therapeutics that in...
Introgen in Medical Technology
Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
... LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 -
introgen Therapeutics,
Inc. (NASDAQ:INGN) reported updated ...plied a
biomarker to obtain regulatory approval.
introgen has officially amended its Phase 3 statistical ana...y elevated levels of p53 protein in tumor
tissues.
introgen believes that application of molecular and
clinica...
Preclinical Studies Identify Novel Approach for Enhancing the
Anticancer Activity of Introgen's INGN 241
...preclinical models of human tumors.
Researchers at
introgen and The University of Texas M. D. Anderson
Cancer ...ssor of clinical
pathology at Columbia University.
introgen holds an exclusive
worldwide sublicense to the Col...therapy applications from GlaxoSmithKline.
About
introgen
...
Introgen and Clinical Collaborators to Report New Results with
Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
...ter and poster presentation
by Robert Sobol, M.D.,
introgen Therapeutics, Inc.
ASGT
-- Role of the Immune ...ton State Convention Center by
Sunil Chada, Ph.D.,
introgen Therapeutics, Inc.
About
introgen Therapeutics, Inc.
...
Introgen's Advexin Demonstrates Clinical Benefit in Inherited
Cancer
...for European markets by Gendux AB, a
subsidiary of
introgen Therapeutics, Inc. The European Medicines
Agency (...and 3 clinical trials conducted
worldwide.
About
introgen Therapeutics, Inc.
introgen Therapeutics, Inc. is a biopharmaceutical company
...
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241
in Patients With Advanced Solid Tumors
... SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 -
introgen Therapeutics, Inc.
(NASDAQ:INGN) reported promisin...ssor of clinical
pathology at Columbia University.
introgen holds an exclusive
worldwide sublicense to the Col...therapy applications from GlaxoSmithKline.
About
introgen
...
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved
Survival, Tumor Responses and Predictive p53 Biomarker
... CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 -
introgen Therapeutics, Inc.
(NASDAQ: INGN) and the Company'...y elevated levels of p53 protein in tumor
tissues.
introgen believes that application of molecular and
clinica...p;
Sylvester Comprehensive Cancer Clinics.
About
introgen
...
More>>
Introgen in Biological News
Abnormal overexpression of p53 is a predictive molecular biomarker
...ith treatment of p53 tumor suppressor gene therapy - making it potentially the first predictive biomarker test for a gene-based drug.
Researchers at
introgen Therapeutics, Inc., in Austin, Texas, found that patients with advanced squamous cell carcinoma of the head and neck cancer (SCCHN) whose pre-treatmen...
Introgen in Biological Technology
World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.
...cademic institutions. Leading biotech companies operating in gene therapy marketplace include AnGes MG Inc, Cell Genesys, GenVec, Genzyme Corporation,
introgen Therapeutics Inc, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Targeted Genetics Corp, Transgene, Urigen Pharmaceuticals Inc., and Vical.
...